Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2023): Palazzo A+, ESMO Open Mar, Online ahead of print5% [REVIEW]
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
Adverse reactions attributed to entire drug class 'Poly (ADP-ribose) polymerase (PARP) inhibitor'
Please login to view adverse reactions.
Gastrointestinal adverse reaction
- (2020): Hao J+, Crit Rev Oncol Hematol Nov, Online ahead of print [REVIEW]
- (2023): Maiorano BA+, Target Oncol Nov, Online ahead of print [REVIEW] (association)
- (2021): Zeng J+, Zhonghua Fu Chan Ke Za Zhi (Chinese) 56(6), 401-40740%
- (2024): Dai MF+, Expert Rev Anticancer Ther May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2021): Liu X+, Front Oncol Oct (e-Collection) [REVIEW]
- (2021): Zhang M+, J Cancer Res Ther 17(7), 1672-1678 [REVIEW]
- (2020): Hao J+, Crit Rev Oncol Hematol Nov, Online ahead of print [REVIEW]
- (2020): Jiang Y+, Front Oncol Jul (e-Collection) [REVIEW]
- (2020): Morice PM+, Lancet Haematol Dec, Online ahead of print [REVIEW]
- (2020): Morice PM+, Lancet Haematol Dec, Online ahead of print [REVIEW]
Neutropenia (neutrophils decreased)
- (2023): Maiorano BA+, Target Oncol Nov, Online ahead of print [REVIEW] (association)
Thrombocytopenia / platelets decreased
- (2023): Maiorano BA+, Target Oncol Nov, Online ahead of print [REVIEW] (association)
Adverse effects / adverse reactions
- (2024): Uekusa R+, Sci Rep Jun, Online ahead of print (181 patients with ovarian cancer who received olaparib or niraparib)
- (2023): Cecere SC+, Expert Opin Drug Saf Sep, Online ahead of print
- (2023): Society Of Obstetrics And Gynecology OZMA+, Zhejiang Da Xue Xue Bao Yi Xue Ban 51(6), 765-774 [REVIEW]
- (2022): Luo J+, Front Oncol Jun (e-Collection) [REVIEW]
- (2022): Yamaoka K+, Life (Basel) 12(9), 1355 [REVIEW]
- (2021): Jesus M+, Expert Opin Drug Saf Oct, Online ahead of print [REVIEW]
- (2020): Shao F+, Biosci Rep Feb, Epub ahead of print55% (grade 3–4 (serious, 26%)) [REVIEW]
- (2020): Xu Y+, Front Oncol Feb (e-Collection) [REVIEW]
- (2020): Yang Y+, World J Surg Oncol 18(1), 151 [REVIEW]
